BMAL1 Drives Cisplatin Resistance in Non‐Small Cell Lung Cancer Via Lactate‐ MRP1 Signaling Pathway
Thoracic Cancer · 2026-04 · 17 (8)
DOI: 10.1111/1759-7714.70279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 24.04.2026. Verfasst von Zixin Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory of Tumor Microenvironment, Wannan Medical University, Wuhu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ARNTL Transcription Factors, Cisplatin, Lung Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Program for Excellent Sci-tech Innovation Teams of Universities in Anhui Province, Provincial-level Quality Project in Higher Education Institutions of Anhui Province.
Abstract (Originalsprache)
Lung cancer, the leading cause of cancer‐related mortality, faces significant therapeutic challenges due to chemoresistance. While metabolic reprogramming and circadian disruptions are implicated in tumor progression, their interplay in driving resistance remains unclear. This study identifies BMAL1, a core circadian regulator, as a key driver and potential initiator of cisplatin resistance in non‐small cell lung cancer (NSCLC) through metabolic and oxidative stress pathways. We demonstrate that BMAL1 upregulates multidrug resistance protein MRP1 via HIF‐1α‐driven glycolysis, amplifying lactate production. Lactate activates the TAZ/c‐Jun/Snail complex to increase MRP1 expression, establishing a feedforward loop that sustains chemoresistance. Furthermore, cisplatin and etoposide induce BMAL1 expression through AKT signaling in response to oxidative stress, creating a self‐reinforcing resistance mechanism. Critically, targeting AKT or MRP1 reverses BMAL1‐mediated resistance. These findings reveal BMAL1 as a metabolic orchestrator linking circadian dysfunction to chemoresistance and propose actionable strategies—such as AKT inhibition or chronotherapy—to circumvent therapeutic failure. This work underscores the necessity of targeting circadian‐metabolic crosstalk to improve outcomes in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Laboratory of Tumor Microenvironment, Wannan Medical University, Wuhu, China.
- School of Anesthesiology, Wannan Medical University, Wuhu, China.
- School of Pharmacy, Wannan Medical University, Wuhu, China.
- School of Medical Imageology, Wannan Medical University, Wuhu, China.
- School of Clinical Medicine, Wannan Medical University, Wuhu, China.
- Anhui Province Key Laboratory of Basic Research and Transformation of Age-Related Diseases, Wannan Medical University, Wuhu, China.
ORCID-Profile: Zhihao Wu
Förderung
- National Natural Science Foundation of China
- Program for Excellent Sci-tech Innovation Teams of Universities in Anhui Province
- Provincial-level Quality Project in Higher Education Institutions of Anhui Province
- National College Students Innovation and Entrepreneurship Training Program
- Anhui Provincial Key Science Foundation for Outstanding Young Talent
- Health Science Research Project of Anhui Province
- 2023 Annual Key Project Research Fund of Wannan Medical College
- Natural Science Foundation of the Higher Education Institutions of Anhui Province
Zitieren
APA
Shi, Z., Qin, Z., Chen, C., Yang, X., Hu, Y., Meng, X., Cao, Y., Tao, X., Zhang, Z., Xie, T., Wei, H., & Wu, Z. (2026). BMAL1 Drives Cisplatin Resistance in Non‐Small Cell Lung Cancer Via Lactate‐ MRP1 Signaling Pathway. Thoracic Cancer, 17(8). https://doi.org/10.1111/1759-7714.70279
Vancouver
Shi Z, Qin Z, Chen C, Yang X, Hu Y, Meng X, et al. BMAL1 Drives Cisplatin Resistance in Non‐Small Cell Lung Cancer Via Lactate‐ MRP1 Signaling Pathway. Thoracic Cancer. 2026;17(8). doi:10.1111/1759-7714.70279
BibTeX
@article{Shi2026,
author = {Shi, Zixin and Qin, Ziniu and Chen, Chuantao and Yang, Xiaolin and Hu, Yunhan and Meng, Xiaohui and Cao, Yuxiang and Tao, Xiang and Zhang, Zhijian and Xie, Tiancheng and Wei, Huijun and Wu, Zhihao},
title = {BMAL1 Drives Cisplatin Resistance in Non‐Small Cell Lung Cancer Via Lactate‐ MRP1 Signaling Pathway},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {8},
doi = {10.1111/1759-7714.70279}
}
EUVIMED